医学
微量白蛋白尿
内科学
糖尿病
2型糖尿病
2型糖尿病
干预(咨询)
内分泌学
疾病
精神科
作者
Peter Gæde,Pernille Vedel,Hans‐Henrik Parving,Oluf Pedersen
出处
期刊:The Lancet
[Elsevier BV]
日期:1999-02-01
卷期号:353 (9153): 617-622
被引量:989
标识
DOI:10.1016/s0140-6736(98)07368-1
摘要
Background In type 2 diabetes mellitus the aetiology of long-term complications is multifactorial. We carried out a randomised trial of stepwise intensive treatment or standard treatment of risk factors in patients with microalbuminuria. Methods In this open, parallel trial patients were allocated standard treatment (n=80) or intensive treatment (n=80). Standard treatment followed Danish guidelines. Intensive treatment was a stepwise implementation of behaviour modification, pharmacological therapy targeting hyper-glycaemia, hypertension, dyslipidaemia, and microalbuminuria. The primary endpoint was the development of nephropathy (median albumin excretion rate >300 mg per 24 h in at least one of the two-yearly examinations). Secondary endpoints were the incidence or progression of diabetic retinopathy and neuropathy. Findings The mean age was 55·1 years (SD 7·2) and patients were followed up for 3·8 years (0·3). Patients in the intensive group had significantly lower rates of progression to nephropathy (odds ratio 0·27 [95% CI 0·10–0·75]), progression of retinopathy (0·45 [0·21–0·95]), and progression of autonomic neuropathy (0·32 [0·12–0·78]) than those in the standard group. Interpretation Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria slows progression to nephropathy, and progression of retinopathy and autonomic neuropathy. However, further studies are needed to establish the effect of intensified multifactorial treatment on macrovascular complications and mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI